The DP receptor, allergic inflammation and asthma

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 69, Issue 2-3, 2003, Pages 187-194

  Kabashima, Kenji ^a   Narumiya, Shuh ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Allergy; Asthma; Colitis; Conjunctivitis; DP; Inflammation; Pain; Prostaglandin D2; Skin; Sleep

Indexed keywords

5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 9BETA CHLORO 15 CYCLOHEXYL 9 DEOXY 16,17,18,19,20 PENTANORPROSTAGLANDIN F2 ALPHA; ARACHIDONIC ACID; CELL SURFACE RECEPTOR; CHEMOATTRACTANT RECEPTOR; COMPLEMENTARY DNA; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN SYNTHASE; RECEPTOR; SQ 27986; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ALLERGY; ASTHMA; ATOPIC DERMATITIS; COLITIS; HOMEOSTASIS; HUMAN; INFLAMMATION; MAST CELL; MOLECULAR CLONING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SKIN ALLERGY; TH2 CELL;

EID: 0042623534     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(03)00080-2     Document Type: Article

References (58)

1. 2 generation after activation of rat and human mast cells with anti-IgE, J. Immunol. 129 (1982) 1627-1631.
2. 2 into human airways during acute antigen challenge, N. Engl. J. Med. 315 (1986) 800-804.
3. E.N. Charlesworth, A. Kagey-Sobotka, P.S. Norman, L.M. Lichtenstein, H.A. Sampson, Cutaneous late-phase response in food-allergic children and adolescents with atopic dermatitis, Clin. Exp. Allergy 23 (1993) 391-397.
4. 2 from human skin in vivo and in vitro during immediate allergic reactions, Br. J. Pharmacol. 94 (1988) 773-780.
5. R.M. Naclerio, H.L. Meier, N.F. Adkinson Jr., A. Kagey-Sobotka, D.A Meyers, P.S. Norman, L.M. Lichtenstein, In vivo demonstration of inflammatory mediator release following nasal challenge with antigen, Eur. J. Respir. Dis. Suppl. 128 (1983) 26-32.
6. D. Proud, J. Sweet, P. Stein, R.A. Settipane, A. Kagey-Sobotka, M.H. Friedlaender, L.M. Lichtenstein, Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen, J. Allergy Clin. Immunol. 85 (1990) 896-905.
7. N.A. Soter, R.A. Lewis, E.J. Corey, K.F. Austen, Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4 and LTB4) in human skin, J. Invest. Dermatol. 80 (1983) 115-119.
8. D.J. Heavey, P. Lumley, S.E. Barrow, M.B. Murphy, P.P. Humphrey, C.T. Dollery, Effects of intravenous infusions of prostaglandin D2 in man, Prostaglandins 28 (1984) 755-767.
9. S. Narumiya, Y. Sugimoto, F. Ushikubi, Prostanoid receptors: structures, properties, and functions, Physio. Rev. 79 (1999) 1193-1226.
10. 2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven-transmembrane receptor CRTH2, J. Exp. Med. 193 (2001) 255-261.
11. M. Hirata, A. Kakizuka, M. Aizawa, F. Ushikubi, S. Narumiya, Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene, Proc. Natl. Acad. Sci. USA 91 (1994) 11192-11196.
12. Y. Boie, N. Sawyer, D.M. Slipetz, K.M. Metters, M. Abramovitz, Molecular cloning and characterization of the human prostanoid DP receptor, J. Biol. Chem. 270 (1995) 18910-18916.
13. 2 is suggested by distribution studies of the rat DP prostanoid receptor, Eur. J. Pharmacol. 377 (1999) 101-115.
14. H. Toh, A. Ichikawa, S. Narumiya, Molecular evolution of receptors for eicosanoids, FEBS Lett. 361 (1995) 17-21.
15. T. Kobayashi, M. Kiriyama, T. Hirata, M. Hirata, F. Ushikubi, S. Narumiya, Identification of domains conferring ligand binding specificity to the prostanoid receptor. Studies on chimeric prostacyclin/prostaglandin D receptors, J. Biol. Chem. 272 (1997) 15154-15160.
16. T. Kobayashi, F. Ushikubi, S. Narumiya, Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors; identification by site-directed mutagenesis, J. Biol. Chem. 275 (2000) 24294-24303.
17. 2: a biochemical perspective, Prostaglandins Leukot. Essent. Fatty Acids 37 (1989) 219-234.
18. 2 receptors, Prostaglandins 25 (1983) 13-28.
19. 2 (DP) receptors: estimation of affinities and relative efficacies for a series of novel bicyclic ligands (with an appendix on goodness-of-fit analyses), Br. J. Pharmacol. 106 (1992) 996-1003.
20. 2-receptor, Prostaglandins 35 (1988) 855-868.
21. 2-analogues, Adv. Prostaglandins Thromboxane Leukot. Res. 21 (1990) 591-594.
22. J.Y. Crider, B.W. Griffin, N.A. Sharif, Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists, Br. J. Pharmacol. 127 (1999) 204-210.
23. H. Giles, P. Leff, M.L. Bolofo, M.G. Kelly, D. Robertson A, The classification of prostaglandin DP-receptors in platelets vasculature using BW A868C, a novel, selective and potent competitive antagonist, Br. J. Pharmacol. 96 (1989) 291-300.
24. 2 and BW245C activation of human platelet adenylate cyclase, Br. J. Pharmacol. 96 (1989) 301-306.
25. - secretion in dog tracheal epithelium, Eur. J. Pharmacol. 304 (1996) 117-122.
26. R.J. Keery, P. Lumley, AH6809, a prostaglandin DP-receptor blocking drug on human platelets, Br. J. Pharmacol. 94 (1988) 745-754.
27. M. Kiriyama, F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, S. Narumiya, Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells, Br. J. Pharmacol. 122 (1997) 217-224.
28. D.H. Wright, K.M. Metters, M. Abramovitz, A.W. Ford-Hutchinson, Characterization of the recombinant human prostanoid DP receptor and identification of L-644 698 a novel selective DP agonist, Br. J. Pharmacol. 123 (1998) 1317-1324.
29. 2 receptor antagonists, J. Med. Chem. 40 (1997) 3504-3507.
30. A. Arimura, K. Yasui, J. Kishino, et al., Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751, J. Pharmacol. Exp. Ther. 298 (2001) 411-419.
31. C.S. Murray, A. Woodcock, A. Custovic, The role of indoor allergen exposure in the development of sensitization and asthma, Curr. Opin. Allergy Clin. Immunol. 1 (2001) 407-412.
32. L. Maddox, D.A. Schwartz, The pathophysiology of asthma, Annu. Rev. Med. 53 (2002) 477-498.
33. 2 as a mediator of allergic asthma, Science 287 (2000) 2013-2017.
34. A.F. Walls, Y.K. Rhee, D.J. Gould, et al., Inflammatory mediators and cellular infiltration of the lungs in a guinea pig model of the late asthmatic reaction, Lung 169 (1991) 227-240.
35. Y. Fujitani, Y. Kanaoka, K. Aritake, N. Uodome, K. Okazaki-Hatake, Y. Urade, Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice, J. Immunol. 168 (2002) 443-449.
36. S.T. Holgate, The inflammation-repair cycle in asthma: the pivotal role of the airway epithelium, Clin. Exp. Allergy 28 (1998) 97-103.
37. C.L. Chan, R.L. Jones, H.Y. Lau, Characterization of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells, Br. J. Pharmacol. 129 (2000) 589-597.
38. 2 causes accumulation of eosinophils in the lumen of the dog trachea, J. Appl. Physiol. 67 (1989) 959-962.
39. 2 receptors CRTH2 and DP, J. Allergy Clin. Immunol. 108 (2001) 982-988.
40. 2 in normal and asthmatic men, N. Engl. J. Med. 311 (1984) 209-213.
41. S.L. Johnston, P.G. Bardin, J. Harrison, W. Ritter, J.R. Joubert, S.T. Holgate, The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations, Br. J. Clin. Pharmacol. 34 (1992) 402-408.
42. N. al Jarad, K.P. Hui, N. Barnes, Effects of a thromboxane receptor antagonist on prostaglandin D2 and histamine induced bronchoconstriction in man, Br. J. Clin. Pharmacol. 37 (1994) 97-100.
43. A.M. Dvorak, R.A. Monahan, J.E. Osage, G.R. Dickersin, Mast-cell degranulation in Crohn's disease, Lancet 1 (1978) 498.
44. H.J. Kaufmann, H.L. Taubin, Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease, Ann. Intern. Med. 107 (1987) 513-516.
45. K. Kabashima, T. Saji, T. Murata, et al., The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut, J. Clin. Invest. 109 (2002) 883-893.
46. M.N. Ajuebor, A. Singh, J.L. Wallace, Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis, Am. J. Physiol. Gastrointest. Liver Physiol. 279 (2000) G238-244.
47. 2, Prostaglandins 35 (1988) 277-300.
48. K.E. Barrett, Effect of histamine and other mast cell mediators on T84 epithelial cells, Ann. N Y Acad. Sci. 664 (1992) 222-231.
49. D.H. Wright, A.W. Ford-Hutchinson, K. Chadee, K.M. Metters, The human prostanoid DP receptor stimulates mucin secretion in LS174T cells, Br. J. Pharmacol. 131 (2000) 1537-1545.
50. J. Banchereau, R.M. Steinman, Dendritic cells and the control of immunity, Nature 392 (1998) 245-252.
51. 2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection, J. Exp. Med. 193 (2001) 1135-1147.
52. 2 inhibits fibroblast migration, Eur. Respir. J. 19 (2002) 684-689.
53. O. Hayaishi, Molecular mechanisms of sleep-wake regulation: a role of prostaglandin D2, Philos. Trans. R. Soc. Lond. Ser. B 355 (2000) 275-280.
54. H. Oida, M. Hirata, Y. Sugimoto, et al., Expression of messenger RNA for the prostaglandin D receptor in the leptomeninges of the mouse brain, FEBS Lett. 417 (1997) 53-56.
55. A. Mizoguchi, N. Eguchi, K. Kimura, et al., Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep, Proc. Natl. Acad. Sci. USA 98 (2001) 11674-11679.
56. D. Gerashchenko, C.T. Beuckmann, Y. Kanaoka, et al., Dominant expression of rat prostanoid DP receptor mRNA in leptomeninges, inner segments of photoreceptor cells, iris epithelium, and ciliary processes, J. Neurochem. 71 (1998) 937-945.
57. B. Kilunga Kubata, N. Eguchi, Y. Urade, et al., Plasmodium falciparum produces prostaglandins that are pyrogenic, somnogenic, and immunosuppressive substances in humans, J. Exp. Med. 188 (1998) 1197-1202.
58. 2 in patients with systemic mastocytosis, N. Engl. J. Med. 303 (1980) 1400-1404.